ZS acquires bioinformatics and systems biology company, Intomics A/S
4.5.2022 16:00:00 EEST | Business Wire | Press release
The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics. Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development by enabling complex analysis of biomedical data. The addition of renowned scientists to the ZS team will strengthen ZS’s focus on the discovery of new medicines for all.
Global pharmaceutical and biotech companies, along with other biomedical research entities, use Intomics’s service and technology offerings to assist in preclinical work, including target discovery, biomarker identification, drug repositioning and patient stratification. As the pharmaceutical industry intensifies its efforts on developing novel drugs, demand for innovative capabilities in discovery and disease biology is growing.
Intomics’s highly curated and best-in-class protein-protein interaction network is condition-agnostic and supports tailored biomedical analysis spanning multiple diseases. Scientists and bioinformaticians use the network to understand disease biology at the pathway and molecular level. This drives novel insights and discoveries and accelerates preclinical activities to ultimately bring new medicines to patients faster.
“Our strategic acquisition of Intomics will allow us to assist our clients in pursuing breakthrough science and innovative medicines that profoundly improve patients’ lives,” said Pratap Khedkar, CEO of ZS. “Combined, our unique mix of deep data, academic and scientific expertise, technology and artificial intelligence will ultimately accelerate drug discovery and improve the probability of success for innovative medicines.”
The 42 members of Intomics will join ZS’s staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, data science and technology expertise with a research mindset to advance the adoption of in-silico methods in drug discovery. The addition of Intomics expands upon ZS’s existing data and technology offerings to bring further sophistication in leveraging analytics, bioinformatics and applied mathematics to drive business impact for the science of R&D.
“For us, ZS was a natural destination to build on our legacy. Through integration with ZS, we will be able to broaden our impact in drug discovery, increase the scale and use of AI in our client work and operate on a global scale while expanding career opportunities for our team members,” said Thomas S. Jensen, Ph.D., CEO and co-founder of Intomics. “Our shared roots in academia and shared values, including a commitment to rigor, a deliberative approach and doing right by both our clients and our staff, made ZS a natural fit for us and for our clients,” he continued.
About ZS
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 12,000-plus ZSers in 30-plus offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
About Intomics
Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers who share a passion for translating data to cures. And we’ve proudly done so for more than 10 years. We collaborate closely with our clients in the biotech and pharmaceutical industry, and we harness the synergy between our clients’ specific disease knowledge and our unique data analytics expertise and technology. Together we make a difference for patients. This is both our trademark and what drives the people of Intomics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005267/en/
Contact information
Quintin Maidment
ZS@TheBlissGrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Unveils Mastering Skin Longevity, a Breakthrough Scientific Innovation Platform Advancing the Next Era of Skin Science6.11.2026 16:00:00 EET | Press release
At the China International Import Expo (CIIE), The Estée Lauder Companies Inc. (NYSE: EL) today unveiled Mastering Skin Longevity, a breakthrough scientific innovation platform designed to advance the next era of skin science and transformative product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106776704/en/ The Estée Lauder Companies' Skin Longevity Clock serves as the visual representation for the Mastering Skin Longevity scientific innovation platform. Moving beyond the study of individual Hallmarks of Aging, the platform focuses further upstream on the Master Regulators of Skin Longevity. These interconnected biological pathways and proteins influence multiple hallmarks at once. By deepening understanding of these systems and how they help support skin’s ability to repair, adapt and regenerate, Mastering Skin Longevity will guide the Company’s discovery across ingredients, technologies, formulations an
IntouchCX Recognized for Operations led AI and End to End CX Transformation by HFS Research6.11.2026 16:00:00 EET | Press release
IntouchCX a global leader in AI-powered customer experience (CX) management, trust and safety, digital engagement, and back-office operations, has been positioned in the Horizon 2 end-to-end experience transformation, in the HFS Horizons Customer Experience Services 2026 report for its operations led approach to AI adoption and its model connecting advisory with delivery, from strategy through frontline executions. HFS Research evaluates customer experience service providers based on their capabilities, innovation, and potential to deliver value. The 2026 report examines how providers are helping businesses adopt AI, improve customer experiences and strengthen operations. “AI transformation delivers the greatest value when strategy, technology, and operations work together,” said Brent Stevenson, Chief Experience Officer at IntouchCX. “Our approach and expertise goes beyond technology. We identify business challenges and build the right solutions by connecting the dots between data, wo
Experian Named a Leader in 2026 IDC MarketScape for Worldwide Decision Intelligence Platforms6.11.2026 16:00:00 EET | Press release
Experian today announced it has been named a Leader in the IDC MarketScape: Worldwide Decision Intelligence Platforms 2026 Vendor Assessment (Doc #US54118426, September 2026), which evaluates providers helping organizations design, engineer and orchestrate increasingly complex decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106302874/en/ IDC MarketScape positions Experian as a Leader in its 2026 vendor assessment of worldwide decision intelligence platform providers. “As organizations embed AI into more consequential decisions, the combination of trusted data, advanced analytics and strong governance becomes increasingly important,” said Keith Little, President of Experian Software Solutions. “Experian brings those capabilities together with decisioning, fraud and identity to help organizations make better decisions with greater speed and confidence.” The Experian Ascend Platform provides a unified analytics and
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 13:04:00 EET | Press release
Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading European producer of uncoated woodfree (UWF) paper for office and commercial printing. Its product portfolio spans cut-size office paper, sold under its own brands such as REY and Multicopy as well as on behalf of major OEM and office supplies customers, and paper reels for commercial printers and converters. Headquartered in Belgium, with two large-scale, vertically integrated pulp and paper mills, it serves a longstandi
Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex6.11.2026 01:23:00 EET | Press release
Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history. Adjusted EBITDA totaled R$5.7 billion in 3Q26, up 9% on the same basis of comparison. Operating cash generation reached R$3.8 billion, an increase of 12%. Net income totaled R$2.1 billion. As announced following the completion of the transaction with Kimberly-Clark, Suzano holds a 51% equity interest in Arbex and will therefore fully consolidate the joint venture’s financial statements from this quarter onwards.1 “This quarter marks the beginning of a new phase for Suzano. With Arbex, we are now a broader business, both ge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom